Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
- PMID: 28546454
- PMCID: PMC5669140
- DOI: 10.1161/JAHA.116.004007
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Abstract
Background: The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral hypoglycemic agents. We undertake a systematic review and meta-analysis of prospective studies to determine the effect of SGLT2 on blood pressure (BP) among individuals with type 2 diabetes mellitus.
Methods and results: PubMed-Medline, Web of Science, Cochrane Database, and Google Scholar databases were searched to identify trial registries evaluating the impact of SGLT2 on BP. Random-effects models meta-analysis was used for quantitative data synthesis. The meta-analysis indicated a significant reduction in systolic BP following treatment with SGLT2 (weighted mean difference -2.46 mm Hg [95% CI -2.86 to -2.06]). The weighted mean differences for the effect on diastolic BP was -1.46 mm Hg (95% CI -1.82 to -1.09). In these subjects the weighted mean difference effects on serum triglycerides and total cholesterol were -2.08 mg/dL (95% CI -2.51 to -1.64) and 0.77 mg/dL (95% CI 0.33-1.21), respectively. The weighted mean differences for the effect of SGLT2 on body weight was -1.88 kg (95% CI -2.11 to -1.66) across all studies. These findings were robust in sensitivity analyses.
Conclusions: Treatment with SGLT2 glucose cotransporter inhibitors therefore has beneficial off-_target effects on BP in patients with type 2 diabetes mellitus and may also be of value in improving other cardiometabolic parameters including lipid profile and body weight in addition to their expected effects on glycemic control. However, our findings should be interpreted with consideration for the moderate statistical heterogeneity across the included studies.
Keywords: Sodium‐glucose cotransport‐2 inhibitors; blood pressure; diabetes mellitus; meta‐analysis.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Figures
Similar articles
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2017 May 18;6(5):e005686. doi: 10.1161/JAHA.117.005686. J Am Heart Assoc. 2017. PMID: 28522675 Free PMC article. Review.
-
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27822054 Free PMC article. Review.
-
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556. Curr Diabetes Rev. 2017. PMID: 27296042 Free PMC article. Review.
-
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.J Am Heart Assoc. 2021 Feb;10(5):e019463. doi: 10.1161/JAHA.120.019463. Epub 2021 Feb 24. J Am Heart Assoc. 2021. PMID: 33625242 Free PMC article.
-
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0. Cardiovasc Diabetol. 2017. PMID: 28241822 Free PMC article. Clinical Trial.
Cited by
-
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.Int J Mol Sci. 2021 Apr 23;22(9):4441. doi: 10.3390/ijms22094441. Int J Mol Sci. 2021. PMID: 33922865 Free PMC article. Review.
-
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.Cardiovasc Diabetol. 2021 Apr 7;20(1):78. doi: 10.1186/s12933-021-01266-x. Cardiovasc Diabetol. 2021. PMID: 33827579 Free PMC article. Review.
-
Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series.J Am Coll Cardiol. 2018 Oct 9;72(15):1829-1844. doi: 10.1016/j.jacc.2018.07.081. J Am Coll Cardiol. 2018. PMID: 30286928 Free PMC article. Review.
-
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis.Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221142450. doi: 10.1177/20420188221142450. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 36533186 Free PMC article.
-
Kidney and heart failure outcomes associated with SGLT2 inhibitor use.Nat Rev Nephrol. 2022 May;18(5):294-306. doi: 10.1038/s41581-022-00535-6. Epub 2022 Feb 10. Nat Rev Nephrol. 2022. PMID: 35145275 Review.
References
-
- Mazidi M, Heidari‐Bakavoli A, Khayyatzadeh SS, Azarpazhooh MR, Nematy M, Safarian M, Esmaeili H, Parizadeh SM, Ghayour‐Mobarhan M, Kengne AP, Ferns GA. Serum hs‐CRP varies with dietary cholesterol, but not dietary fatty acid intake in individuals free of any history of cardiovascular disease. Eur J Clin Nutr. 2016;70:1454–1457. - PubMed
-
- Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162–172. - PubMed
-
- Gæde P, Lund‐Andersen H, Parving H‐H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591. - PubMed
-
- del Cañizo‐Gómez FJ, Moreira‐Andrés MN. Cardiovascular risk factors in patients with type 2 diabetes: do we follow the guidelines? Diabetes Res Clin Pract. 2004;65:125–133. - PubMed
-
- Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials. J Diabetes Complications. 2016;8:77–83. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical